

Product Information

Ribonuclease A from bovine pancreas

Sigma Type X-A, ≥90% (SDS-PAGE), ≥70 Kunitz units/mg protein, buffered aqueous solution

R5250

Product Description

CAS Registry Number: 9001-99-4

Enzyme Commission (EC) Number: 3.1.27.5

Synonyms: RNase A, Pancreatic ribonuclease, Ribonuclease 3'-pyrimidinooligonucleotidohydrolase, Ribonuclease I, Endoribonuclease I

Molecular mass:¹ 13.7 kDa (based on amino acid sequence)

Extinction coefficient:² $E^{1\%} = 7.1$ (280 nm)

Isoelectric point:³ pI = 9.6

Optimal temperature: 60 °C (activity range of 15-70 °C)

Optimal pH:⁴ 7.6 (activity range of 6-10)

Inhibitors: ribonuclease inhibitor

RNase A is an endoribonuclease that attacks at the 3'-phosphate of a pyrimidine nucleotide. For example, RNase A will cleave pG-pG-pC-pA-pG to give pG-pG-pCp and A-pG. The highest activity is exhibited with single-stranded RNA.⁵

RNase A is a single chain polypeptide with 4 disulfide bridges. In contrast to RNase B, RNase A is not a glycoprotein.⁶ RNase A can be inhibited by alkylation of His¹² or His¹¹⁹ (present in the active site of the enzyme).⁷ Activators of RNase A include potassium and sodium salts.

Several dissertations⁸⁻¹³ have cited use of product R5250 in their protocols.

Product

This product is a solution in 0.2 M sodium phosphate buffer, pH 6.4. The acceptable protein concentration range is ≥ 10 mg/mL.

Storage/Stability

Store this RNase A solution product at -20 °C.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Usage

A major application for RNase A is the removal of RNA from preparations of plasmid DNA. For this application, DNase-free RNase A is used at a final concentration of 10 µg/mL.¹⁴

References

1. Smyth, D.G. *et al.*, *J. Biol. Chem.*, **238**(1), 227-234 (1963).
2. Keller, P.J. *et al.*, *J. Biol. Chem.*, **233**(2), 344-349 (1958).
3. Tanford, C., and Hauenstein, J. D., *J. Am. Chem. Soc.*, **78**(20), 5287-5291 (1956).
4. Schomberg, D., and Salzmann, M., *Enzyme Handbook*, Vol. 3, 1-3, under EC 3.1.27.5 (1990).
5. Burrell, M.M., *Methods Mol. Biol.*, **16**, 263-270 (1993).
6. Plummer, T.H., Jr., and Hirs, C.H.W., *J. Biol. Chem.*, **238**(4), 1396-1401 (1963).
7. Heinrikson, R.L. *et al.*, *J. Biol. Chem.*, **240**(7), 2921-2934 (1965).

8. Ferreira de Carvalho, António Paulo Alves, "Utilização de hidrolisados proteicos em dietas microparticuladas para larvas de carpa (*Cyprinus carpio*) e robalo (*Dicentrarchus labrax*)" ["Use of protein hydrolysates in microparticulate diets for carp (*Cyprinus carpio*) and sea bass (*Dicentrarchus labrax*) larvae"]. Universidade do Porto, Ph.D. dissertation, p. 55 (2000).
9. Swenson, Joel Mathew, "Identification and Characterization of Novel Regulators of Heterochromatin Structure and Function". University of California Berkeley, Ph.D. dissertation, p. 105 (2013).
10. Vasiliauskaite, Lina, "Embryonic Functions of Reprogramming Mutants *Miwi2*, *Mili* and *Dnmt3L* Influence Adult Male Germline Maintenance". Ruperto-Carola-Universität Heidelberg, Dr. rer. nat. dissertation, p. 43 (2016).
11. Strom, Amy Rose, "Phase Transitions in Nuclear Organization and Function". University of California Berkeley, Ph.D. dissertation, p. 43 (2018).
12. Lutyj, Paul, "Modulation der Strahlensensibilität mittels alleiniger sowie kombinierter PI3K/mTOR-Inhibierung im Glioblastommodell: die Rolle des PTENs" ("Modulation of radiosensitivity using sole and combined PI3K/mTOR inhibition in the glioblastoma model: the role of the PTEN"). Julius-Maximilians-Universität Würzburg, Dr. med. dissertation, p. 145 (2018).
13. Grabenbauer, Felix, "Radiosensibilisierung humaner Tumorzelllinien unterschiedlicher Entitäten durch den MEK-Inhibitor PD184352 allein oder in Kombination mit dem HSP90-Inhibitor NVP-AUY922: Einfluss der Behandlungsschemas" ("Radiosensitization of human tumor cell lines from different entities by the MEK inhibitor PD184352 alone or in combination with the HSP90 inhibitor NVP-AUY922: influence of the treatment regimens"). Julius-Maximilians-Universität Würzburg, Dr. med. dissertation, p. 25 (2021).

14. Sambrook, J., and Russell, D.W., *Molecular Cloning, A Laboratory Manual* (3rd ed). Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY), Volume 1, 1.78-1.79 (2001).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://www.sigmaaldrich.com/techservice).

Standard Warranty

The applicable warranty for the products listed in this publication may be found at [SigmaAldrich.com/terms](https://www.sigmaaldrich.com/terms).

Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://www.sigmaaldrich.com/offices).

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

R5250pis Rev 07/22 RBG,MAM,KTA,GCY

**MILLIPORE
SIGMA**